Enovis (ENOV) Competitors $33.34 -0.21 (-0.61%) Closing price 06/11/2025 03:59 PM EasternExtended Trading$34.63 +1.29 (+3.86%) As of 08:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENOV vs. STVN, GKOS, NARI, IRTC, TMDX, BLCO, INSP, SLNO, PRCT, and NVSTShould you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Soleno Therapeutics (SLNO), PROCEPT BioRobotics (PRCT), and Envista (NVST). These companies are all part of the "medical equipment" industry. Enovis vs. Its Competitors Stevanato Group Glaukos Inari Medical iRhythm Technologies TransMedics Group Bausch + Lomb Inspire Medical Systems Soleno Therapeutics PROCEPT BioRobotics Envista Stevanato Group (NYSE:STVN) and Enovis (NYSE:ENOV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings, community ranking and dividends. Is STVN or ENOV more profitable? Stevanato Group has a net margin of 10.47% compared to Enovis' net margin of -5.95%. Stevanato Group's return on equity of 9.86% beat Enovis' return on equity.Company Net Margins Return on Equity Return on Assets Stevanato Group10.47% 9.86% 5.79% Enovis -5.95%4.39%2.80% Do insiders & institutionals have more ownership in STVN or ENOV? 98.4% of Enovis shares are held by institutional investors. 0.7% of Stevanato Group shares are held by company insiders. Comparatively, 2.7% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer STVN or ENOV? Enovis received 4 more outperform votes than Stevanato Group when rated by MarketBeat users. Likewise, 66.04% of users gave Enovis an outperform vote while only 63.27% of users gave Stevanato Group an outperform vote. CompanyUnderperformOutperformStevanato GroupOutperform Votes3163.27% Underperform Votes1836.73% EnovisOutperform Votes3566.04% Underperform Votes1833.96% Which has stronger valuation & earnings, STVN or ENOV? Stevanato Group has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStevanato Group$1.12B6.67$157.62M$0.5148.57Enovis$2.15B0.89-$33.26M-$13.95-2.39 Which has more risk and volatility, STVN or ENOV? Stevanato Group has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Enovis has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Does the media prefer STVN or ENOV? In the previous week, Stevanato Group had 1 more articles in the media than Enovis. MarketBeat recorded 5 mentions for Stevanato Group and 4 mentions for Enovis. Stevanato Group's average media sentiment score of 1.14 beat Enovis' score of 0.87 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend STVN or ENOV? Enovis has a consensus price target of $58.00, suggesting a potential upside of 73.94%. Given Enovis' higher probable upside, analysts clearly believe Enovis is more favorable than Stevanato Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86Enovis 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryStevanato Group beats Enovis on 11 of the 18 factors compared between the two stocks. Get Enovis News Delivered to You Automatically Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENOV vs. The Competition Export to ExcelMetricEnovisSurgical appliances & supplies IndustryMedical SectorNYSE ExchangeMarket Cap$1.90B$9.31B$5.57B$19.81BDividend YieldN/A1.26%5.28%3.83%P/E Ratio-15.2321.0327.1435.67Price / Sales0.8944.12411.9846.74Price / Cash6.8619.6738.2517.52Price / Book0.535.227.064.84Net Income-$33.26M$284.66M$3.23B$1.02B7 Day Performance5.54%0.83%2.85%1.94%1 Month Performance-9.07%-4.38%9.06%3.03%1 Year Performance-26.14%-20.92%31.43%9.73% Enovis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENOVEnovis2.7567 of 5 stars$33.34-0.6%$58.00+73.9%-25.5%$1.90B$2.15B-15.236,800STVNStevanato Group2.2721 of 5 stars€22.01-0.9%N/A+36.4%$6.67B$1.12B46.834,650Positive NewsGKOSGlaukos4.4309 of 5 stars$94.89+0.6%$134.67+41.9%-12.3%$5.42B$404.52M-33.06780NARIInari Medical0.5254 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800News CoverageIRTCiRhythm Technologies1.3218 of 5 stars$140.65+0.1%$133.73-4.9%+59.0%$4.49B$618.59M-38.641,790Analyst ForecastTMDXTransMedics Group1.3599 of 5 stars$123.94-2.5%$126.70+2.2%+2.8%$4.19B$488.23M131.85210BLCOBausch + Lomb3.9002 of 5 stars$11.46-0.1%$15.50+35.3%-16.3%$4.05B$4.83B-12.5912,500Analyst ForecastINSPInspire Medical Systems4.7896 of 5 stars$133.66-3.3%$211.91+58.5%-19.9%$3.94B$840.11M77.26760Positive NewsSLNOSoleno Therapeutics4.8226 of 5 stars$75.66+3.1%$106.78+41.1%+70.5%$3.81BN/A-22.7930Positive NewsAnalyst RevisionGap UpPRCTPROCEPT BioRobotics1.9139 of 5 stars$57.94-0.1%$90.00+55.3%-7.4%$3.21B$249.12M-29.71430NVSTEnvista3.4015 of 5 stars$18.09-1.0%$20.23+11.8%+5.9%$3.07B$2.50B-2.7912,700 Related Companies and Tools Related Companies Stevanato Group Competitors Glaukos Competitors Inari Medical Competitors iRhythm Technologies Competitors TransMedics Group Competitors Bausch + Lomb Competitors Inspire Medical Systems Competitors Soleno Therapeutics Competitors PROCEPT BioRobotics Competitors Envista Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ENOV) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enovis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.